These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Clinical response to PD-1 blockade correlates with a sub-fraction of peripheral central memory CD4+ T cells in patients with malignant melanoma. Takeuchi Y; Tanemura A; Tada Y; Katayama I; Kumanogoh A; Nishikawa H Int Immunol; 2018 Feb; 30(1):13-22. PubMed ID: 29294043 [TBL] [Abstract][Full Text] [Related]
8. Pembrolizumab joins the anti-PD-1 armamentarium in the treatment of melanoma. Hersey P; Gowrishankar K Future Oncol; 2015; 11(1):133-40. PubMed ID: 25572788 [TBL] [Abstract][Full Text] [Related]
9. PD-1 and TIGIT coexpression identifies a circulating CD8 T cell subset predictive of response to anti-PD-1 therapy. Simon S; Voillet V; Vignard V; Wu Z; Dabrowski C; Jouand N; Beauvais T; Khammari A; Braudeau C; Josien R; Adotevi O; Laheurte C; Aubin F; Nardin C; Rulli S; Gottardo R; Ramchurren N; Cheever M; Fling SP; Church CD; Nghiem P; Dreno B; Riddell SR; Labarriere N J Immunother Cancer; 2020 Nov; 8(2):. PubMed ID: 33188038 [TBL] [Abstract][Full Text] [Related]
11. CTLA-4 and PD-1/PD-L1 blockade: new immunotherapeutic modalities with durable clinical benefit in melanoma patients. Ott PA; Hodi FS; Robert C Clin Cancer Res; 2013 Oct; 19(19):5300-9. PubMed ID: 24089443 [TBL] [Abstract][Full Text] [Related]
12. TIGIT and PD-1 impair tumor antigen-specific CD8⁺ T cells in melanoma patients. Chauvin JM; Pagliano O; Fourcade J; Sun Z; Wang H; Sander C; Kirkwood JM; Chen TH; Maurer M; Korman AJ; Zarour HM J Clin Invest; 2015 May; 125(5):2046-58. PubMed ID: 25866972 [TBL] [Abstract][Full Text] [Related]
13. Reduction of T Lymphoma Cells and Immunological Invigoration in a Patient Concurrently Affected by Melanoma and Sezary Syndrome Treated With Nivolumab. Narducci MG; Tosi A; Frezzolini A; Scala E; Passarelli F; Bonmassar L; Monopoli A; Accetturi MP; Cantonetti M; Antonini Cappellini GC; De Galitiis F; Rosato A; Picozza M; Russo G; D'Atri S Front Immunol; 2020; 11():579894. PubMed ID: 33072126 [TBL] [Abstract][Full Text] [Related]
14. Programmed death-1 & its ligands: promising targets for cancer immunotherapy. Shrimali RK; Janik JE; Abu-Eid R; Mkrtichyan M; Khleif SN Immunotherapy; 2015; 7(7):777-92. PubMed ID: 26250412 [TBL] [Abstract][Full Text] [Related]